International Society

Veradigm Presentations at ISPOR 2022 Highlight Broader Access to and Integration of Real-world Data Sources

Retrieved on: 
Wednesday, May 11, 2022
Software, General Health, Health, Data Management, Technology, Mobile, Wireless, Other Technology, Other Health, Real-World Evidence, EHR, American College of Cardiology, EDT, American College, YouTube, Twitter, Real, NASDAQ, COVID-19, Heart failure, SARS-COV-2, International Society for Pharmacoeconomics and Outcomes Research, Mining, Health, Cardiovascular disease, Infection, Research, Lorenzo patient record systems, Use, RWD, Patient, Electronic health record, Caregiver, Risk, Pharmacoeconomics, Diagnosis, Diabetes, Fatty liver disease, Practice Fusion, Connected, Technique, LinkedIn, NASH, RWE, Solution, Dashboard, Technology, Allscripts, MDRX, International Society, Multimedia, Pharmaceutical industry, Medical imaging, Perfume, Facebook

Key data presentations at ISPOR 2022 include:

Key Points: 
  • Key data presentations at ISPOR 2022 include:
    SARS-COV-2 Vaccine Breakthrough Infection Rates Based Data from 3 EHRS .
  • Comparing Fibrosis Staging Approaches Among Patients with Non-Alcoholic Steatohepatitis (NASH) Using Real World Data (RWD) .
  • Veradigm is a healthcare technology company that drives value through its unique combination of platforms, data, expertise, connectivity, and scale.
  • For more information on Veradigm, visit www.veradigm.com , or find Veradigm on LinkedIn, Facebook, Twitter, and YouTube.

IACAPAP: April 23 has been declared the World Infant, Child and Adolescent Mental Health Day (WICAPHK) by the world’s leading psychiatric organizations for child and adolescence

Retrieved on: 
Wednesday, May 11, 2022
American Academy of Child and Adolescent Psychiatry, Infant mental health, Population, United States Public Health Service, Psychiatry, Society, International Association for Child and Adolescent Psychiatry and Allied Professions, Policy, Element, Prevalence, Child and Adolescent Mental Health, WPA, Adolescence, Trauma, Caregiver, Associate, Infant, ACeS, International Association, Diagnosis, Lists of diseases, World Association for Sexual Health, Knowledge, Multilateralism, Publication, Disability, Learning, Adult, Health, Education, Adverse childhood experiences, Life, Mental health, Goal, International Society, Ownership, Growth, Awareness, Birth control, Medicine, Toy, Residential care, IACAPAP, Child, Research, Psychology

We hope to change this with the World Infant Child and Adolescent Mental Health Day, by relooking our priorities and having the right reasons for planning our future.

Key Points: 
  • We hope to change this with the World Infant Child and Adolescent Mental Health Day, by relooking our priorities and having the right reasons for planning our future.
  • This is the reason for celebrating the World Infant, Child and Adolescent Mental Health Day,
    The designation of Apr 23 as WICAMHD draws recognition of the importance of infant, child and adolescent mental health; and encourages stakeholders to advocate for the promotion of mental health and prevention of mental illness in the young by:
    Improving global public awareness about infant, child and adolescent mental health.
  • Creating literacy and competencies in the promotion of infant, child and adolescent mental health as well as reducing the stigma of mental disorders in these populations.
  • Contributing to education programs and research, meetings, and publications to increase knowledge about child and adolescent mental disorders and skills in addressing them.

David C. Pollock is recognized by Continental Who's Who

Retrieved on: 
Tuesday, May 10, 2022
Elective surgery, Hobby, International Society for Technology in Education, Department, CSA OrthoCarolina Sportsplex, Health, American Board of Orthopaedic Surgery, ABOS, Physician, Hip, Time, Wake Forest School of Medicine, William H. Harris (orthopaedic surgeon), Patient, Holy, Holy, Holy! Lord God Almighty, General surgery, Association, Loving Memory, Adult, American Association, Royal Society University Research Fellowship, Wake Forest Baptist Medical Center, Continental, American Academy, American Board of Surgery, Carolinas, Wake Forest University, Technology, International Society, Mentorship, American Academy of Orthopaedic Surgeons, American Board of Commissioners for Foreign Missions, Multimedia, Medical device, Dentistry, Arthroplasty, Biology, Orthopedic surgery, Medicine

With over two decades in Medical practice, David C. Pollock is an expert in hip and knee replacements.

Key Points: 
  • With over two decades in Medical practice, David C. Pollock is an expert in hip and knee replacements.
  • Dr. Pollock attended Wake Forest University, earning a Bachelor of Arts degree in Biology in 1984.
  • Dr. Pollock completed an Adult Reconstruction Fellowship in Alexandria, VA, from 1999-2000, gaining more experience with hip and knee replacement procedures.
  • Today, Dr. Pollock serves as the Section Chief of Orthopaedic Surgery at Orthopaedics Davie - Wake Forest Baptist Health in Bermuda Run, NC.

DOWN TO ONE HAIR TRANSPLANTATION PROCEDURE FROM 3.4 TO ACHIEVE DESIRED RESULT

Retrieved on: 
Tuesday, May 10, 2022
Workplace, COVID-19, Woman, Hair loss, Man, Physician, Research, Patient, Platelet-rich plasma, Male, Diagnosis, PRP, Female, Education, International Society, Bachelor of Medicine, Bachelor of Surgery, Multimedia, Health insurance, Dentistry

CHICAGO, May 10, 2022 /PRNewswire/ -- According to results of a new member survey conducted by the International Society of Hair Restoration Surgery (ISHRS), 68% of members reported performing an average of one procedure per patient in 2021 to achieve the desired hair restoration result. This represents a significant improvement, as ISHRS members estimated an average of 3.4 procedures in 2019 and 5 procedures in 2016 were needed per patient to achieve the desired result.

Key Points: 
  • CHICAGO, May 10, 2022 /PRNewswire/ -- According to results of a new member survey conducted by the International Society of Hair Restoration Surgery (ISHRS), 68% of members reported performing an average of one procedure per patient in 2021 to achieve the desired hair restoration result.
  • This represents a significant improvement, as ISHRS members estimated an average of 3.4 procedures in 2019 and 5 procedures in 2016 were needed per patient to achieve the desired result.
  • With now refined Follicular Unit Transplantation techniques both linear excision and follicular unit excision male and female patients are benefiting from the latest advances."
  • ISHRS physicians evaluate each patient's hair loss individually and recommend treatment options based on the specific diagnosis and the patient's expectations.

Dr. David Vigerust of Spectrum Solutions to Deliver Keynote Address at ISBER 2022

Retrieved on: 
Tuesday, May 10, 2022
Biotechnology, General Health, Health, Science, Research, Laboratory, Solution, Biology, ISBER, LLC, Engineering, Patient, Biophysical environment, Industry, International Society for Biological and Environmental Repositories, Disease, Science, Education, Technology, International Society, Research, Multimedia, Pharmaceutical industry

Spectrum Solutions , LLC today announced its Chief Scientific Officer, David Vigerust, MS, Ph.D. will be delivering this years keynote address in Atlanta, Georgia, at the International Society for Biological and Environmental Repositories (ISBER) annual meeting and conference.

Key Points: 
  • Spectrum Solutions , LLC today announced its Chief Scientific Officer, David Vigerust, MS, Ph.D. will be delivering this years keynote address in Atlanta, Georgia, at the International Society for Biological and Environmental Repositories (ISBER) annual meeting and conference.
  • View the full release here: https://www.businesswire.com/news/home/20220510005371/en/
    Dr. David Vigerust of Spectrum Solutions will deliver the keynote address at ISBER 2022.
  • Dr. Vigerusts keynote address will reflect the evolving vision for the future of biobanking as seen through the lens of a scientist and dedicated investigator.
  • We believe when you bridge the gap between science and real medical solutions, you deliver innovation with the practical power to impact and change outcomes.

Baebies Partners with Medical Horizons to Bring SEEKER Newborn Screening Platform to Italy

Retrieved on: 
Tuesday, May 10, 2022
Infant, Glycogen storage disease type II, Medical Horizons, Fabry, Pompe, Microfluidics, Gambling, Gods and LSD, Partnership, Digital microfluidics, FDA, Meyer Children's Hospital, Hospital, Glycogen storage disease, Newborn screening, Adoption, CEO, Technology, Research, International Society, Entrepreneurship, Medical device, Pharmaceutical industry, Mucopolysaccharidosis

FLORENCE, Italy, May 10, 2022 /PRNewswire/ -- Baebies, a growth-stage medical device company developing innovative products to enable early disease detection and multifunctional diagnostic testing for children and adults., in partnership with medical device supplier Medical Horizons, today announced newborns in Italy are being screened with the Baebies SEEKER platform.

Key Points: 
  • FLORENCE, Italy, May 10, 2022 /PRNewswire/ -- Baebies, a growth-stage medical device company developing innovative products to enable early disease detection and multifunctional diagnostic testing for children and adults., in partnership with medical device supplier Medical Horizons, today announced newborns in Italy are being screened with the Baebies SEEKER platform.
  • Powered by digital microfluidics technology, SEEKER is an FDA-cleared and CE-marked newborn screening platform for LSDs.
  • Dr. la Marca is a recognized global authority in newborn screening, who works closely with the International Society for Neonatal Screening to advance research and adoption of newborn screening around the world.
  • However, an amendment to current newborn screening legislation could expedite inclusion of new conditions like LSDs in screening panels around the country.

ASME and Black & Veatch Launch Twinify Technologies to Provide Digital Twin Solutions

Retrieved on: 
Monday, May 9, 2022
Construction & Property, Consulting, Engineering, Professional Services, Technology, Other Construction & Property, Manufacturing, Other Technology, Mechanical engineering, Water, LLC, ASME, OEM, Black, International relations, Partnership, Industry, Artificial intelligence, ISIE, Leadership, Black & Veatch, American Society of Mechanical Engineers, Efficiency, Society, Education, Solution, Technology, International Society, Social media, Management, Risk management

The American Society of Mechanical Engineers (ASME) and Black & Veatch announced today the launch of a new joint venture, Twinify Technologies LLC , to provide digital twin solutions serving clients in asset intensive industries.

Key Points: 
  • The American Society of Mechanical Engineers (ASME) and Black & Veatch announced today the launch of a new joint venture, Twinify Technologies LLC , to provide digital twin solutions serving clients in asset intensive industries.
  • Headquartered in New York, Twinify will operate through a partnership between the International Society of Interdisciplinary Engineers (ISIE) LLC, a for-profit subsidiary of ASME, and Black & Veatch.
  • ASME has long been a leader in performance test codes and operating standards that can elevate the performance and capabilities of digital twin services.
  • As part of the new companys operations, nDimensional, a leader in digital twin enablement, will aid Twinify in the delivery of advanced digital twin solutions.

Enlivex Presented Substantial Survival Benefit of Allocetra in Combination with Immune Checkpoint Inhibitor in Mesothelioma Cancer Study at the International Society for Cell and Gene Therapy Annual 2022 Meeting

Retrieved on: 
Monday, May 9, 2022
People, CAR, Immune system, Mouse, GLOBE, Cell, Poster, Patient, Immunotherapy, Immunosuppression, Gene, Survival, Metastasis, Macrophage, FDA, AB12, Cancer, Tams, Mechanic, CTLA4, Asbestos, Chimeric antigen receptor T cell, Survival rate, International Society, Risk, Therapy, Pharmaceutical industry, Mesothelioma

The poster was titled, Allocetra-OTS, an Early Apoptotic Cellular Therapy Synergize with Chimeric Antigen Receptor (CAR) T Cell Therapy or Immune Check Point Inhibitor Against Peritoneal Solid Tumor.

Key Points: 
  • The poster was titled, Allocetra-OTS, an Early Apoptotic Cellular Therapy Synergize with Chimeric Antigen Receptor (CAR) T Cell Therapy or Immune Check Point Inhibitor Against Peritoneal Solid Tumor.
  • Immune checkpoint inhibitors targeting CTLA4 and PD1 are FDA-approved as first-line treatments for patients with unresectable malignant pleural mesothelioma.
  • The TAMs typically form a physical layer on top of the solid tumor, and induce immunosuppression in the solid tumor microenvironment.
  • Enlivex is a clinical-stage macrophage reprogramming immunotherapy company developing Allocetra, a universal, off-the-shelf cell therapy designed toreprogram macrophages into their homeostatic state.

International Society for Cell & Gene Therapy Presentations Illustrate Evox Therapeutics’ Proprietary Exosome Engineering Platform with New Data on Exosome Targeting and In Vivo Distribution

Retrieved on: 
Monday, May 9, 2022
Brain, Karolinska Institute, Exosome, GLOBE, RNA, Engineering, Oxford, Cell, ISCT, Degenerative disease, Delivery, Gene editing, Therapy, EVS, Tissue, ISEV, Science, Technology, International Society, Neoplasm, Seminal vesicles, Central nervous system, Medical device

OXFORD, United Kingdom, May 09, 2022 (GLOBE NEWSWIRE) -- Evox Therapeutics Ltd (Evox or the Company), a leading exosome therapeutics company, announced two oral presentations at the International Society for Cell & Gene Therapy (ISCT) 2022 Meeting, May 4 to 7, in San Francisco.

Key Points: 
  • OXFORD, United Kingdom, May 09, 2022 (GLOBE NEWSWIRE) -- Evox Therapeutics Ltd (Evox or the Company), a leading exosome therapeutics company, announced two oral presentations at the International Society for Cell & Gene Therapy (ISCT) 2022 Meeting, May 4 to 7, in San Francisco.
  • The presentations were part of the ISCT 1-day Scientific Signature series Therapeutic Advances with Native and Engineered Human EVs.
  • Samir El Andaloussi, Ph.D., Evox co-founder and Professor at the Karolinska Institut, presented on EV Engineering for Directed Loading and Delivery of Biotherapeutics.
  • Evox is backed by leading life sciences venture capital groups including Redmile and Orbimed, and is supported by a comprehensive intellectual property portfolio.

Theramex Launches Non-hormonal Femarelle® on the 12th of May

Retrieved on: 
Monday, May 9, 2022
Health, Consumer, Women, General Health, Pharmaceutical, Biotechnology, Birth, Gynecological Endocrinology, Fertility, HRT, Congress, Woman, Patient, Menopause, Health, Osteoporosis, Life, Solution, International Society, Awareness, Health insurance, Medical device, Theramex

Theramex will be joining the 20th International Society of Gynecological Endocrinology (ISGE) congress from the 11th-14th May in Florence, Italy.

Key Points: 
  • Theramex will be joining the 20th International Society of Gynecological Endocrinology (ISGE) congress from the 11th-14th May in Florence, Italy.
  • Theramex are very proud to introduce Femarelle which Theramex will commercialize in Italy, France, Spain, Germany, UK, Belgium, Poland and Australia.
  • Femarelle is a non-hormonal food supplement developed to help women manage symptoms in perimenopause, with Femarelle Rejuvenate1; menopause, with Femarelle Recharge2; and post-menopause, with Femarelle Unstoppable3.
  • As Camilla Harder Hartvig, Chief Commercial Officer at Theramex says "we are delighted to add Femarelle to our already broad portfolio of prescription products to treat menopause symptoms.